PFE - IPO Update: Vaxcyte Proceeds With IPO Plan
Quick Take
Vaxcyte (PCVX) intends to raise $210 million in an IPO of its ordinary shares, per an amended registration statement.
The company is developing a family of vaccines for pneumococcal and other global markets.
PCVX is a very early stage, preclinical vaccine researcher and the IPO may be more suited to institutional venture investors rather than individuals.
Company & Technology
Foster City, California-based Vaxcyte was founded to utilize its cell-free protein synthesis platform to design and produce protein carriers and antigens to target the multi billion dollar global pneumococcal vaccine market.